BioSpace News Archive

Aerovate Therapeutics, Inc. announced that Company management will present at the Jefferies Global Healthcare Conference on Wednesday, June 7, at 8:00 a.m. ET, which presentation will include an overview of AV-101 and the IMPAHCT Phase 2b/Phase 3 trial.

Avadel Pharmaceuticals plc announced that members of management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8 at 1:00 p.m. ET.

Ocular Therapeutix, Inc. announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023 at 12:30 PM EDT at the Marriott Marquis in New York, NY.

Eyenovia, Inc. announced that the company will be delivering a presentation at the annual OCTANE Ophthalmology Tech Forum 2023, which is being held June 8-9 in Newport Beach, CA.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be highlighting new studies and the recent expansion of its Precise™ Oncology Solutions portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023.

PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD), and other serious conditions with intractable neurologic symptoms, today announced that the eligibility review and final enrollment for the company’s Real World Evidence study (HAT-301) has been completed.

Pasithea Therapeutics Corp. announced that pre-clinical results for its lead drug candidate, PAS-004, have been accepted for a poster presentation at the 2023 Neurofibromatosis Conference taking place June 24-27, 2023, in Scottsdale, Arizona.

Portage Biotech Inc. announced that CEO Dr. Ian Walters will serve as an expert spokesperson on an oncology panel discussion at the upcoming BIO International Conference taking place in Boston, Massachusetts June 5-8, 2023.

Angion Biomedia Corp., a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) announced today that the U.S. Food and Drug Administration (“FDA”), after reviewing safety data on the program, has removed the partial clinical hold on patient enrollment for its MT-0169 trial.